<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885883</url>
  </required_header>
  <id_info>
    <org_study_id>2011-A00285-36</org_study_id>
    <secondary_id>2011-04</secondary_id>
    <nct_id>NCT02885883</nct_id>
  </id_info>
  <brief_title>Non-invasive Quantification of Atrial Fibrosis by MRI in Atrial Fibrillation</brief_title>
  <acronym>QUAFI</acronym>
  <official_title>Non-invasive Quantification of Atrial Fibrosis by MRI in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three groups of patients will be considered: a control group (n = 10); a group of patients
      with paroxysmal or persistent AF with AF cryoablation procedure - within this group, MRI will
      replace CT-scan usually performed in routine before the procedure (n = 15); a group of
      patients with permanent AF (n = 15). MRI study will include pulmonary veins angiography with
      gadolinium injection (0.20 mmol/kg), 2D-cine imaging and late-enhancement imaging. A 3D
      gradient-echo sequence(Flash 3-D) will then be applied 20 minutes after the injection, with
      the following parameters : echo time 0.98 ms, repetition time 2.53 ms, angle 15°, resolution
      2.0x1.3x1.0 mm. T1 map and two T2 sequences will be performed so as to determine LA
      relaxation times. Argus software will be used for post-treatment imaging. Quantitative data
      will be expressed in mean ± SD. A comparison of T1 and T2 values in LA will be performed
      between the three groups. Statistics will be performed with SPSS software in bilateral
      analysis and a value of p &lt; 0.05 will be considered as significant.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>quantitative measure of atrial fibrosis</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>a control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with paroxysmal or persistent AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with permanent AF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI 3T</intervention_name>
    <arm_group_label>a control group</arm_group_label>
    <arm_group_label>patients with paroxysmal or persistent AF</arm_group_label>
    <arm_group_label>patients with permanent AF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All persons &gt; 18 years, which have:

        gp paroxysmal or persistant FA

          1. paroxysmal or persistent FA (under one year),

          2. refractory to at least one antiarrhythmic drug therapy

          3. eligible for an ablation procedure with cryotherapy

          4. the patient may benefit from surveillance. gp permanent FA permanent AF ( defined as
             chronic arrhythmia after 2 failed attempts to electrical cardioversion and / or more
             than one year old) , and hospitalized for cardiac reasons or not in different
             cardiology Timone .

        Exclusion Criteria:

          -  age &lt; 18 years,

          -  cons -indications to MRI ( claustrophobia, pacemakers and implantable cardiac
             defibrillators , metal chips intra ocular , valvular mechanical prosthesis ) , allergy
             to gadolinium ,

          -  renal impairment ( creatinine clearance &lt;60 mL / min)

          -  pregnant or nursing ( a pregnancy test must be performed for women of childbearing age
             at the time of inclusion , the result of this test will be communicated to them .

          -  the MRI examination takes place three months after the inclusion women of childbearing
             potential should be placed under effective contraception)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>catherine GEINDRE</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP HM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>August 26, 2016</last_update_submitted>
  <last_update_submitted_qc>August 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

